Compositions and methods for gene editing

The genetic editing of the Angptl3 genome of the nucleic acid internal acid -guided nucleic acid in the RNA is performed, which solves the problem of Angptl3 -related disease treatment, realizes a significant reduction in Angptl3 protein secretion, and provides a safe and effective treatment plan.

CN119351474APending Publication Date: 2025-01-24CRISPR THERAPEUTICS AG
View PDF 192 Cites 0 Cited by

Patent Information

Application Number
CN202410566670.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2017-11-17
Filing Date
2018-02-21
Publication Date
2025-01-24

Smart Images

  • Figure BDA0004829508090000231
    Figure BDA0004829508090000231
  • Figure BDA0004829508090000931
    Figure BDA0004829508090000931
  • Figure BDA0004829508090000941
    Figure BDA0004829508090000941
Patent Text Reader

Abstract

The present application provides ex vivo or in vivo materials and methods for treating a patient suffering from one or more conditions associated with ANGPTL3. In addition, the present application provides materials and methods for editing and / or modulating the expression of the ANGPTL3 gene in a cell by genome editing.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Compositions and methods for microRNA expression profiling of nasopharyngeal carcinoma

    EP2112235A1

  • annular gap magnet system

    FR901228A

  • Connector assemblies and associated methods

    US11241132B2

  • Nuclease resistant chimeric oligonucleotides

    US20030158403A1

  • Microrna molecules

    US20050059005A1